Ageing - Drug Pipeline Landscape, 2023
Description
Ageing - Drug Pipeline Landscape, 2023
Ageing is the process during which structural and functional changes occur in an organism as a result of the passage of time. The changes manifest as a decline from the organism's peak fertility and physiological functions until death.
Smoking exposes skin to oxidative stress causing dryness, wrinkles, and other signs of premature aging. Tanning beds and exposure to the sun penetrate your skin with UV rays. These rays damage the DNA in skin cells, causing wrinkles. There are some very rare genetic conditions that can cause to show signs of aging in childhood and early puberty.
Signs and symptoms of aging include increased susceptibility to infection, decrease in height as the bones of our spines get thinner and lose some height, joint changes, stooped posture, slowed and limited movement, decrease in overall energy, constipation and urinary incontinence. Ageing can also be prevented with screening tests and immunizations.
Early aging, treatments that use retinoids, vitamin C, and alpha hydroxy acids may be enough. Chemical peels, dermabrasion, microneedling, ultrasound energy devices, or laser resurfacing may be an option for moderate to severe facial sun damage.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Ageing treatment such as Longeveron Mesenchymal Stem Cells, Rapamycin, Allogeneic Human Mesenchymal Stem Cells and others. Key players involved in the development of therapies to treat Ageing are AgelessRx, Galapagos NV, Longeveron Inc, RepliCel Life Sciences Inc and others. Three drugs are under clinical-stage Phase II clinical trials and two drugs are in Phase I clinical trials of development.
In October 2022, AgelessRx partnered with Longevity Labs on a descriptive study that has shown positive results for quality-of-life outcomes.
Report Highlights
Global Insight Service's, Ageing - Drug Pipeline Landscape, 2023 report provides an overview of the Ageing pipeline drugs. This report covers detailed insights on Ageing drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Ageing pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Ageing is the process during which structural and functional changes occur in an organism as a result of the passage of time. The changes manifest as a decline from the organism's peak fertility and physiological functions until death.
Smoking exposes skin to oxidative stress causing dryness, wrinkles, and other signs of premature aging. Tanning beds and exposure to the sun penetrate your skin with UV rays. These rays damage the DNA in skin cells, causing wrinkles. There are some very rare genetic conditions that can cause to show signs of aging in childhood and early puberty.
Signs and symptoms of aging include increased susceptibility to infection, decrease in height as the bones of our spines get thinner and lose some height, joint changes, stooped posture, slowed and limited movement, decrease in overall energy, constipation and urinary incontinence. Ageing can also be prevented with screening tests and immunizations.
Early aging, treatments that use retinoids, vitamin C, and alpha hydroxy acids may be enough. Chemical peels, dermabrasion, microneedling, ultrasound energy devices, or laser resurfacing may be an option for moderate to severe facial sun damage.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Ageing treatment such as Longeveron Mesenchymal Stem Cells, Rapamycin, Allogeneic Human Mesenchymal Stem Cells and others. Key players involved in the development of therapies to treat Ageing are AgelessRx, Galapagos NV, Longeveron Inc, RepliCel Life Sciences Inc and others. Three drugs are under clinical-stage Phase II clinical trials and two drugs are in Phase I clinical trials of development.
In October 2022, AgelessRx partnered with Longevity Labs on a descriptive study that has shown positive results for quality-of-life outcomes.
Report Highlights
Global Insight Service's, Ageing - Drug Pipeline Landscape, 2023 report provides an overview of the Ageing pipeline drugs. This report covers detailed insights on Ageing drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Ageing pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
51 Pages
- 1. Introduction
- 1.1 Ageing - Pipeline Drugs, 2023 - Coverage
- 2. Disease Overview - Ageing
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Ageing - Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Clinical Stage Drugs-Phase II
- 5.1.1 Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
- 5.1.2 Longeveron Mesenchymal Stem Cells (LMSCs)
- 5.1.3 Rapamycin
- 5.2 Clinical Stage Drugs-Phase I
- 5.2.1 GLPG1205
- 5.2.2 RCS-01
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 AgelessRx
- 9.2 Galapagos NV
- 9.3 Longeveron Inc.
- 9.4 RepliCel Life Sciences, Inc
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1.1 Number of Products under Development by Ageing
- Table 1.2 Number of Products under Development by Companies
- Table 1.3 Products under Development by Companies
- Table 1.4 Products by Targets
- Table 1.5 Products by Mechanism of Action
- Table 1.6 Products by Molecule Type
- Table 1.7 Products by Route of Administration
- Table 2.1 Clinical Trial Details - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)/Longeveron Inc
- Table 2.2 Clinical Trial Details - Longeveron Mesenchymal Stem Cells (LMSCs)/Longeveron Inc
- Table 2.3 Clinical Trial Details - Rapamycin/Inovio Pharmaceuticals
- Table 2.4 Clinical Trial Details - GLPG1205/Galapagos NV
- Table 2.5 Clinical Trial Details - RCS-01/RepliCel Life Sciences, Inc.
- Table 3.1 Regulatory Designations
- Table 4.1 Inactive Drugs
- Table 4.2 Discontinued Drugs
- List of Figures
- Figure 1.1 Number of Products under Development for Ageing, 2023
- Figure 1.2 Products by Top 5 Targets and Stage of Development for Ageing, 2023
- Figure 1.3 Products by Top 5 Mechanism of Action and Stage of Development for Ageing, 2023
- Figure 1.4 Products by Top 5 Molecule Type and Stage of Development for Ageing, 2023
- Figure 1.5 Products by Top 5 Route of Administration and Stage of Development for Ageing, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
